# Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

> **NCT04340557** · PHASE4 · COMPLETED · sponsor: **Sharp HealthCare** · enrollment: 31 (actual)

## Conditions studied

- SARS-CoV Infection

## Interventions

- **DRUG:** Losartan

## Key facts

- **NCT ID:** NCT04340557
- **Lead sponsor:** Sharp HealthCare
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-27
- **Primary completion:** 2020-06-13
- **Final completion:** 2020-06-13
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04340557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04340557, "Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04340557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*